Loading cancer entity…
Loading cancer entity…
Clinical trials
115 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05950802 | Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta(ODIN) | recruiting | Phase 1 | 40 | University Health Network, TorontoOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07255963 | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL | recruiting | Phase 2 | 29 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 1, 2025 |
| clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07231250 | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | not yet recruiting | Phase 2 | 40 | Li ZhimingOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05621096 | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 33 | University of NebraskaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04079179 | Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders(NACHO-COBI) | recruiting | Phase 2 | 90 | Carl AllenOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07066436 | ImmunoMRI for Assessment of Tumor-associated Macrophages | not yet recruiting | Early Phase 1 | 60 | Medical University of ViennaOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07057765 | Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL | recruiting | — | 40 | Ain Shams UniversityOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02285582 | International Rare Histiocytic Disorders Registry (IRHDR)(IRHDR) | recruiting | — | 400 | The Hospital for Sick ChildrenOTHER | 9 | Jun 24, 2025 | clinicaltrials |
| NCT07034508 | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 | not yet recruiting | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06891157 | Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes | recruiting | Phase 2 | 148 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06151080 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | recruiting | Phase 2 | 38 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158399 | AZA Combined With RCHOP in P53-mutated DLBCL. | recruiting | Phase 2 | 52 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06452446 | Telehealth-based Symptom Management for Veterans Treated With Selinexor(Selinexor) | active not recruiting | — | 20 | Durham VA Medical CenterFED | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06734078 | An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme(POSS) | active not recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06026488 | Real-World Study of DLBCL With Different Genetic Subtypes | recruiting | — | 10,000 | Ruijin HospitalOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
| NCT05641428 | Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL(HOVON161) | recruiting | Phase 2 | 300 | University Medical Center GroningenOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06526065 | Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict) | recruiting | — | 500 | University Medical Center GoettingenOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06299553 | Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) | recruiting | — | 200 | Incyte Biosciences Italy S.r.lINDUSTRY | 1 | May 22, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Dec 8, 2025source: clinicaltrials